SuperworthPacira BioSciences profit margin PCRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- 2.0%
- Operating margin, 12 months
- 2.7%
- Net margin on a year earlier
- +20.0 pts
- Peer median
- 13.3%
Over the twelve months to Jun 30, 2026, Pacira BioSciences kept 2.0% of its revenue as net profit, with an operating margin of 2.7% and a gross margin of 79.2%.
Five years earlier its net margin was 34.6%.
The median for 10 large drugmakers of a similar size is 13.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 1.0% | 2.6% | 79.4% |
| FY2024 | −14.2% | −10.5% | 75.7% |
| FY2023 | 6.2% | 13.0% | 72.6% |
| FY2022 | 2.4% | 9.0% | 70.1% |
| FY2021 | 7.8% | 16.6% | 74.1% |
| FY2020 | 33.9% | 10.8% | 72.7% |
| FY2019 | −2.6% | 2.5% | 74.7% |
| FY2018 | −0.1% | 4.7% | 74.3% |
| FY2017 | −14.9% | −8.7% | 69.3% |
| FY2016 | −13.7% | −11.6% | 60.2% |
| FY2015 | 0.7% | 3.8% | 71.1% |
| FY2014 | −6.9% | −2.6% | 60.8% |
| FY2013 | −74.7% | −62.3% | 36.0% |
| FY2012 | n/a | n/a | 17.8% |
| FY2011 | n/a | n/a | −6.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 2.0% | +20.0 pts | 2.7% | |
| Q1 FY26 | 0.7% | +15.5 pts | 3.3% | |
| Q4 FY25 | 1.0% | +15.2 pts | 2.6% | |
| Q3 FY25 | 3.0% | +16.0 pts | 5.8% | |
| Q2 FY25 | −18.1% | −27.3 pts | −14.8% | |
| Q1 FY25 | −14.8% | −25.1 pts | −12.0% | |
| Q4 FY24 | −14.2% | −20.4 pts | −10.5% | |
| Q3 FY24 | −13.1% | −14.1 pts | −9.3% | |
| Q2 FY24 | 9.2% | +9.9 pts | 13.4% | |
| Q1 FY24 | 10.3% | +11.9 pts | 15.3% | |
| Q4 FY23 | 6.2% | +3.8 pts | 13.0% | |
| Q3 FY23 | 1.0% | −2.1 pts | 6.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Pacira BioSciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| HRMYHarmony Biosciences | 18.9% |
| PBHPrestige Consumer Healthcare | 15.6% |
| ABUSArbutus Biopharma | 84.2% |
| NRIXNurix Therapeutics | 42.0% |
| COLLCollegium Pharmaceutical | 5.9% |
| Peer median | 13.3% |
Where Pacira BioSciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Pacira BioSciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.